9 Critical Pharmaceutical Stories for Industry Leaders

Welcome to today's edition of Press Monitor's curated press review. We track 43 articles across 18 Indian publications to bring you the most impactful developments in pharmaceuticals and life sciences. Here are the 9 stories you need to know.

1. Delhi Police Busts Massive Anti-Cancer Drug Racket

A front-page report in Millennium Post says seventeen people have been arrested and hundreds of vials of life-saving anti-cancer medicines worth around Rs 9 crore were recovered in a multi-state racket busted by Delhi Police’s Crime Branch. The seized drugs include Darzalex, Imfinzi, Erbitux, Opdyta, Gazyva, Bavencio, Adcetris and Keytruda, procured through counterfeit channels and diversion from hospitals and government warehouses.

Why it matters: Counterfeit and diverted cancer drugs put patient lives at risk and erode trust in healthcare supply chains.

Key detail: 17 arrested, drugs worth Rs 9 crore seized including Keytruda, Darzalex, and Imfinzi. The network spanned six cities.

Source: Millennium Post, supported by Indian Express, Morning Standard, Times of India, and others.

Next step: Pharma companies should tighten distribution oversight and report suspicious activity.

2. Pulse Pharma Gets DCGI Nod for Nano Vitamin D3

"Selon The Hindu, Pulse Pharmaceuticals has received approval from the Drugs Controller General of India (DCGI) for its nano-carrier entrapped Vitamin D3 oral dispersion. This approval marks a significant step for the company, transforming advanced nano pharmaceutical research into a regulated, patient-ready product. Founder and MD K. V. Rambabu highlighted that this could be the first of its kind globally, paving the way for Pulse Pharmaceuticals to expand its reach to neighboring South Asian countries and pursue regulatory approvals in markets like the U.S., where the company has five patents in the nano pharmaceutical drug delivery field since 2010."

Why it matters: This is a world-first nanocarrier technology for Vitamin D3, offering 50-60% higher absorption.

Key detail: Founder K.V. Rambabu says this could be the first globally, opening doors to US and South Asian markets.

Source: The Hindu, also covered by Asian Age, Deccan Chronicle, Business Line.

Next step: Watch for Pulse Pharma's expansion into regulated markets.

3. Karnataka Forms SIT to Probe Fake Medicine Racket

A front-page report in Deccan Herald says the government has formed a Special Investigation Team to probe a spurious drug repacking racket operating from a farmhouse near Bidadi. The operation involved impersonating companies like Pfizer and supplying fraudulent medicines from Himachal Pradesh and Telangana, with seized contraband valued at Rs 5 crore.

Why it matters: A Rs 5 crore spurious drug repacking operation impersonated Pfizer and other manufacturers.

Key detail: The SIT, led by DIG C Vamsi Krishna, will investigate the racket busted near Bengaluru.

Source: Deccan Herald, also reported by Morning Standard and The Pioneer.

Next step: Hospitals and pharma distributors must verify supply chain partners.

4. Mankind Pharma Partners with Chenan for Insulin Analogues

A front-page report in Business Line says Mankind Pharma has signed an exclusive agreement with China's Chongqing Chenan Biopharmaceutical Co to commercialise two insulin analogues in India. The partnership focuses on Insulin Degludec and an Insulin Degludec Aspart combination to expand the company's diabetes care portfolio.

Why it matters: This exclusive deal brings two insulin analogues (Insulin Degludec and combination) to India, addressing a major diabetes care gap.

Key detail: Mankind expands its diabetes portfolio with Chongqing Chenan Biopharmaceutical's technology.

Source: Business Line, also in Business Standard and Financial Express.

Next step: Competitors may respond with similar in-licensing deals.

5. Moderna & Merck mRNA Vaccine Shows Melanoma Success

A personalised vaccine developed by Moderna Inc and Merck & Co reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology.

Why it matters: A personalised mRNA vaccine reduced melanoma recurrence in a late-stage trial, reviving confidence in the technology.

Key detail: The INTerpath-OOl trial met primary and secondary endpoints for recurrence-free and distant metastasis-free survival.

Source: Business Line, front-page in Times of India.

Next step: Look for regulatory filings and expansion into other cancers.

6. Trump Names Heidi Overton as FDA Head

A front-page report in Financial Express says President Donald Trump announces Dr. Heidi Overton, a trusted White House aide and medical doctor, as the new head of the Food and Drug Administration. She previously served as deputy director of the Domestic Policy Council and championed several of the president's health initiatives.

Why it matters: Overton is a trusted White House aide and medical doctor who will shape US drug approval policies.

Key detail: She served as deputy director of the Domestic Policy Council and championed Trump's health initiatives.

Source: Financial Express.

Next step: Indian pharma exporters should monitor potential policy shifts.

7. GSK Pharma Q1 Beats Expectations on Innovation Drive

"Selon Business Standard, GlaxoSmithKline (GSK) Pharmaceuticals posted a better-than-expected first-quarter (Q1) performance for the 2026-27 (FY27) period, particularly on revenue. The company also saw expansion in gross and operating profit margins. Brokerages anticipate strong growth in the near term, fueled by innovative products and launches. The stock has significantly outperformed over the past month, rising 21 per cent while the Nifty 500 index remained flat. At a current price of 2,999, the stock trades at 35x its FY27 earnings estimates. The company’s 16.5 per cent growth, after a period of slower expansion, was driven by stronger execution, a portfolio transformation strategy, and a favourable base effect. Notably, the innovation portfolio, accounting for approximately a quarter of headline growth, now represents 7 per cent of total sales, up from 4 per cent in the previous year."

Why it matters: GSK's 16.5% revenue growth was driven by innovative products now representing 7% of sales.

Key detail: Shingles vaccine crossed Rs 100 crore annual sales; stock up 21% in a month.

Source: Business Standard.

Next step: Analysts expect continued growth from the innovation pipeline.

8. GLP-1 Drug Boom Spurs Side-Effect Market

A front-page report in Economic Times says companies are rushing to launch products ranging from foods and beverages to face fillers and collagen skincare supplements to capitalize on the side effects of increasingly popular weight-loss drugs such as glucagon-like peptide medications.

Why it matters: Companies are rushing to launch foods, supplements, and fillers capitalising on weight-loss drug side effects.

Key detail: The trend covers collagen skincare, face fillers, and speciality foods targeting GLP-1 users.

Source: Economic Times.

Next step: Nutraceutical firms should explore this adjacent market.

9. Dr Reddy's Wins Trademark Case Against Razenta

A front-page report in Economic Times says the Delhi High Court has ordered the registrar of trademarks to cancel Razenta Pharmaceuticals’ Daplogin trademark. The court ruled that the mark is deceptively similar to Dr Reddy's Labs' Daplo trademark, as both are used for treating Type-2 diabetes Mellitus.

Why it matters: Delhi High Court cancelled Razenta's 'Daplogin' trademark for being deceptively similar to Dr Reddy's 'Daplo' (diabetes drug).

Key detail: The ruling sets a precedent against deceptive similarity in pharma trademarks.

Source: Economic Times.

Next step: Pharma IP teams should review their trademark portfolios.

This media intelligence roundup is powered by Press Monitor's daily tracking of over 400 Indian print publications. For real-time alerts on any topic, our platform delivers verified print coverage to your messaging channels without adding another dashboard to check.

What pharmaceutical trend should we cover next? Let us know in the comments.